Roberto Chiarle

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.
  2019 L1 No data access

1 assessed by us (0 reproduced) · 406 not yet assessed — every PubMed paper on record, linked below.

• Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation ↗

  HemaSphere · 2026 · PMID 41704549
  not yet assessed
• Author Correction: Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma ↗

  Nature Medicine · 2026 · PMID 41862708
  not yet assessed
• Epstein-Barr virus orchestrates spatial reorganization and immunomodulation in the classic Hodgkin lymphoma tumor microenvironment ↗

  Cell Reports Medicine · 2026 · PMID 41923627
  not yet assessed
• Abstract 5619: First-in-class anaplastic lymphoma kinase (ALK)-specific TCR-T cells induce potent and selective antitumor immunity across ALK-driven human cancers ↗

  Cancer Research · 2026
  not yet assessed
• Abstract 6716: ALK-mRNA vaccine as a new Immunotherapy for ALK+ cancers ↗

  Cancer Research · 2026
  not yet assessed
• Abstract 1542: ALK expression identifies a therapeutically targetable subset of Merkel cell carcinomas responsive to ALK.CAR-T cell therapy alone or in combination with ALK inhibitors ↗

  Cancer Research · 2026
  not yet assessed
• Abstract 7814: Ganglioside targeting: Exerting sweet revenge on neuroblastoma ↗

  Cancer Research · 2026
  not yet assessed
• Abstract 5615: ALK-specific TCR-T cells showed potent and specific activity in ALK-positive anaplastic large cell lymphoma ↗

  Cancer Research · 2026
  not yet assessed
• Tafasitamab plus lenalidomide and R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: results from the phase 3 frontMIND study

  Repository@Nottingham (University of Nottingham) · 2026
  not yet assessed
• Proof of concept for machine learning–based models to predict response to anticancer treatments. ↗

  Journal of Clinical Oncology · 2026
  not yet assessed
• Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial ↗

  The Lancet · 2026 · PMID 42217458
  not yet assessed
• APOBEC3 family enzymes induce chromosomal rearrangements by recurrent patterns and enhance the formation of oncogenic fusions in cancers ↗

  Research Square · 2026
  not yet assessed
• Supplementary Table S6 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• Supplementary Table S2 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• Supplementary Table S5 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• Supplementary Table S3 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• Supplementary Table S4 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• Supplementary Table S1 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2026
  not yet assessed
• EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway ↗

  Cancer Discovery · 2026 · PMID 42329099
  not yet assessed
• CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma. ↗

  Apollo (University of Cambridge) · 2026
  not yet assessed
• Heteroplasmic variants of mitochondrial genome in tumor and normal samples from patients with hematologic malignancies ↗

  Leukemia · 2026 · PMID 42463940
  not yet assessed
• CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma ↗

  Blood · 2026 · PMID 42520200
  not yet assessed
• ALK in cancer: from function to therapeutic targeting ↗

  Nature reviews. Cancer · 2025 · PMID 40055571
  not yet assessed
• HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy ↗

  Leukemia · 2025 · PMID 40175628
  not yet assessed
• Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency ↗

  Blood · 2025 · PMID 40825195
  not yet assessed
• Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells ↗

  Nature Biomedical Engineering · 2025 · PMID 40855124
  not yet assessed
• Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies ↗

  Cancers · 2025 · PMID 41228246
  not yet assessed
• Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma ↗

  iScience · 2025 · PMID 40276769
  not yet assessed
• CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors ↗

  Cancer Immunology Research · 2025 · PMID 41059961
  not yet assessed
• Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  Cancer Immunology Research · 2025 · PMID 39774774
  not yet assessed
• Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma ↗

  eJHaem · 2025 · PMID 39927328
  not yet assessed
• Structural Identification of Major Molecular Determinants for Phosphotyrosine Recognition in Tyrosine Kinases Reveals Tumour Promoting and Suppressive Functions ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025 · PMID 40661594
  not yet assessed
• Development of ALK-directed TCR-T cells with potent and specific anti-tumor activity against ALK-positive anaplastic large cell lymphoma ↗

  Blood · 2025
  not yet assessed
• ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells ↗

  UNC Libraries · 2025
  not yet assessed
• Data from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Figure S1 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S3 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S1 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Data File S1 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S6 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S5 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Figure S1 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Figure S3 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S2 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Supplementary Table S4 from Endogenous CD4<sup>+</sup> T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  2025
  not yet assessed
• Abstract 1509: Discovery of choroid plexus targeted gene therapy to protect cancer chemotherapy-related cognitive impairment ↗

  Cancer Research · 2025
  not yet assessed
• Abstract 2847: Patterns of APOBEC3-mediated chromosomal rearrangements in solid cancers ↗

  Cancer Research · 2025
  not yet assessed
• Abstract 2525: Translating clinically validated antibodies into a multiplexed immunofluorescent panel for the spatial profiling of lymphoid malignancies ↗

  Cancer Research · 2025
  not yet assessed
• Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency ↗

  Oncogene · 2025 · PMID 40316742
  not yet assessed
• Comparative <scp>DNA</scp> Methylation Profiling of Human and Murine <scp>ALK</scp>‐Positive B‐Cell Neoplasms ↗

  Genes Chromosomes and Cancer · 2025 · PMID 40879321
  not yet assessed
• IgM and IgG1 B cell receptors differentially affect B cell fates and dictate the pathogenesis of mature B cell lymphomas ↗

  Science Advances · 2025 · PMID 40880486
  not yet assessed
• HISTONE DEACTYLASE 1 HAS A TUMOR-SUPPRESSIVE ROLE IN EARLY T CELL LYMPHOMAGENESIS ↗

  Leukemia Research · 2025
  not yet assessed
• Abstract B071: ALK.CAR-T cells as a new potential treatment for ALK+ Merkel cell carcinoma ↗

  Molecular Cancer Therapeutics · 2025
  not yet assessed
• Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers ↗

  Molecular Cancer Therapeutics · 2025
  not yet assessed
• 225 ALK.CAR-T cells as a new potential treatment for ALK ⁺ merkel cell carcinoma ↗

  Regular and Young Investigator Award Abstracts · 2025
  not yet assessed
• 1297 ALK-mRNA vaccine as a new immunotherapy for ALK+ cancers ↗

  Regular and Young Investigator Award Abstracts · 2025
  not yet assessed
• Cancers modulate p53 truncal neoantigen display to evade T cell detection ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025 · PMID 41394586
  not yet assessed
• Targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia ↗

  Blood · 2025
  not yet assessed
• Dissecting the whole trajectory of aid-induced genomic instability from mutational activity to chromosomal translocation formation ↗

  Blood · 2025
  not yet assessed
• Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia ↗

  Current Issues in Molecular Biology · 2025 · PMID 41614795
  not yet assessed
• Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer ↗

  Cells · 2025 · PMID 41440011
  not yet assessed
• Supplementary Figure S2 from Endogenous CD4⁺ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  Figshare · 2025
  not yet assessed
• Supplementary Data File S1 from Endogenous CD4⁺ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  Figshare · 2025
  not yet assessed
• Supplementary Figure S3 from Endogenous CD4⁺ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  Figshare · 2025
  not yet assessed
• Supplementary Figure S1 from Endogenous CD4⁺ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood ↗

  Figshare · 2025
  not yet assessed
• Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial ↗

  The Lancet Oncology · 2024 · PMID 39270702
  not yet assessed
• Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers ↗

  Nature Communications · 2024 · PMID 38877018
  not yet assessed
• First-hit <i>SETBP1</i> mutations cause a myeloproliferative disorder with bone marrow fibrosis ↗

  Blood · 2024 · PMID 38194688
  not yet assessed
• Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance ↗

  Leukemia · 2024 · PMID 39424708
  not yet assessed
• Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma ↗

  British Journal of Cancer · 2024 · PMID 39478125
  not yet assessed
• Impact of ALK inhibitors to potentiate ALK.CAR‐T therapy in neuroblastoma ↗

  Clinical and Translational Medicine · 2024 · PMID 38877641
  not yet assessed
• HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients ↗

  Discover Oncology · 2024 · PMID 39692827
  not yet assessed
• Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2024 · PMID 38659938
  not yet assessed
• Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers ↗

  Research Square · 2024 · PMID 38313284
  not yet assessed
• Abstract 404: LINE-1 retrotransposition promotes chromosomal translocations through RNA-templated DNA repair in human cancers ↗

  Cancer Research · 2024
  not yet assessed
• Abstract 21: Discovery of ALK-specific TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers ↗

  Cancer Research · 2024
  not yet assessed
• Abstract 50: ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells ↗

  Cancer Research · 2024
  not yet assessed
• Abstract 403: APOBEC3 enzymes induce chromosomal translocations in solid cancer ↗

  Cancer Research · 2024
  not yet assessed
• Activity of the MEK inhibitor trametinib in a patient with a <i>BRAF</i> mutation persisting from T‐lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia ↗

  Pediatric Blood & Cancer · 2024 · PMID 38532250
  not yet assessed
• Distinct and Overlapping Patterns of Chromosomal Translocations Induced by AID and APOBEC3 Family Proteins in Cancer ↗

  SSRN Electronic Journal · 2024
  not yet assessed
• 438 Development of ALK TCR-T therapy against ALK-positive human cancers ↗

  Regular and Young Investigator Award Abstracts · 2024
  not yet assessed
• Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma ↗

  Blood · 2024
  not yet assessed
• Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing ↗

  Nature Communications · 2023 · PMID 36639728
  not yet assessed
• ERα-associated translocations underlie oncogene amplifications in breast cancer ↗

  Nature · 2023 · PMID 37198482
  not yet assessed
• SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  Cancer Discovery · 2023 · PMID 37682219
  not yet assessed
• ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells ↗

  Cancer Cell · 2023 · PMID 38039964
  not yet assessed
• ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer ↗

  Nature Cancer · 2023 · PMID 37430060
  not yet assessed
• Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma ↗

  Science Translational Medicine · 2023 · PMID 37379367
  not yet assessed
• DNA repair mechanisms that promote insertion-deletion events during immunoglobulin gene diversification ↗

  Science Immunology · 2023 · PMID 36961908
  not yet assessed
• Effects of blocking <scp>CD24</scp> and <scp>CD47</scp> ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia ↗

  Journal of Cellular and Molecular Medicine · 2023 · PMID 37654003
  not yet assessed
• A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia ↗

  Hematological Oncology · 2023 · PMID 37016899
  not yet assessed
• Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma ↗

  Frontiers in Oncology · 2023 · PMID 36698412
  not yet assessed
• Mediastinal Gray-Zone Lymphoma: Still an Open Issue ↗

  Hemato · 2023
  not yet assessed
• Gray-Zone Lymphoma: A Still Open Issue ↗

  Preprints.org · 2023
  not yet assessed
• First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis ↗

  Blood · 2023
  not yet assessed
• Data from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Figure 1 from The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration ↗

  2023
  not yet assessed
• Supplementary Figure 2: Revised May 4, 2009 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 4 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Legends for Figures 1-7, Movies 1-6 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 6 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Figures 1-7 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Figures 1-7 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Legends for Figures 1-7, Movies 1-6 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Data from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 1 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 5 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 2 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 1 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 2 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 3 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 6 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 5 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 3 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Figure 2: Revised May 4, 2009 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Movie 4 from The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  2023
  not yet assessed
• Supplementary Figures S1-S4 from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Supplementary Tables S1-S7 from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Data from The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration ↗

  2023
  not yet assessed
• Data from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Data from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 2 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 3 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figures S1-S4 from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-5 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 5 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 4 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figures 1-19 from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Supplementary Figure Legends from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Supplementary Tables S1-S7 from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Supplementary Table S1 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S2 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Materials and Methods from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Table S2 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration ↗

  2023
  not yet assessed
• Supplementary Figure 5 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 2 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 1 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-5 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 4 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure 3 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Table S1 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S3 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S1 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Materials and Methods from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Table S2 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S4 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Table S3 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S2 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Table S3 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S4 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S1 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure S3 from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Supplementary Figure Legends from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Supplementary Figures 1-19 from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Data from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Supplementary Figures from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Abstract 313: Mechanisms of oncogenic tyrosine kinase fusion formation and selection in human cancers ↗

  Cancer Research · 2023
  not yet assessed
• Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Supplementary Figures from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Supplementary Figure Legends from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL ↗

  HemaSphere · 2023
  not yet assessed
• Correction: The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase ↗

  Journal of Cell Science · 2023 · PMID 37855734
  not yet assessed
• Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers ↗

  Molecular Oncology · 2023 · PMID 37872865
  not yet assessed
• Supplementary Video 1 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Video 1 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Figure S1 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Data from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Figure S2 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Data from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Figure S1 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Video 2 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Video 2 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Supplementary Figure S2 from SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment ↗

  2023
  not yet assessed
• Data from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Data from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Data from Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  2023
  not yet assessed
• Data from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  2023
  not yet assessed
• Data from Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  2023
  not yet assessed
• Data from The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration ↗

  2023
  not yet assessed
• Data from Efficacy of a Cancer Vaccine against &lt;i&gt;ALK&lt;/i&gt;-Rearranged Lung Tumors ↗

  2023
  not yet assessed
• Data from NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  2023
  not yet assessed
• Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites ↗

  Nature Communications · 2022 · PMID 35760782
  not yet assessed
• Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy ↗

  Neuron · 2022 · PMID 36070751
  not yet assessed
• Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1 ↗

  Blood · 2022 · PMID 35030251
  not yet assessed
• Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors ↗

  Nature Communications · 2022 · PMID 36153311
  not yet assessed
• A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas ↗

  Blood Advances · 2022 · PMID 35914224
  not yet assessed
• Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma ↗

  Blood · 2022 · PMID 35802834
  not yet assessed
• Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases ↗

  JTO Clinical and Research Reports · 2022 · PMID 36561283
  not yet assessed
• Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma ↗

  Small GTPases · 2022 · PMID 34983288
  not yet assessed
• Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn ↗

  Blood Advances · 2022 · PMID 35090166
  not yet assessed
• Comparative genomic profiling identifies targetable brain metastasis drivers in non-small cell lung cancer ↗

  Research Square · 2022
  not yet assessed
• 317 ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density ↗

  Regular and Young Investigator Award Abstracts · 2022
  not yet assessed
• Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma ↗

  Blood · 2022
  not yet assessed
• Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma ↗

  Figshare · 2022
  not yet assessed
• Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma ↗

  Blood · 2021 · PMID 34657149
  not yet assessed
• Dissecting ELANE neutropenia pathogenicity by human HSC gene editing ↗

  Cell stem cell · 2021 · PMID 33513358
  not yet assessed
• IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions ↗

  Proceedings of the National Academy of Sciences · 2021 · PMID 33526692
  not yet assessed
• Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma ↗

  Blood Advances · 2021 · PMID 34625792
  not yet assessed
• Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 ↗

  Mayo Clinic Proceedings · 2021 · PMID 33673929
  not yet assessed
• CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma ↗

  Blood · 2021
  not yet assessed
• Solving the chromosome puzzle of aneuploidy in cancer ↗

  Genes & Development · 2021 · PMID 34341000
  not yet assessed
• Abstract LT018: The perivascular niche protects ALK+ lymphoma cells from ALK inhibition through the CCL19/21-CCR7 axis ↗

  Cancer Research · 2021
  not yet assessed
• Abstract 1544: Generation of ALK CAR-T cells for neuroblastoma therapy ↗

  Cancer Research · 2021
  not yet assessed
• Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. ↗

  Apollo (University of Cambridge) · 2021
  not yet assessed
• IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma ↗

  Blood · 2020 · PMID 32573700
  not yet assessed
• Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma ↗

  Lung Cancer · 2020 · PMID 32553554
  not yet assessed
• High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells ↗

  Cancers · 2020 · PMID 33066037
  not yet assessed
• A LIBRETTO to orchestrate targeted therapy ↗

  Nature Cancer · 2020 · PMID 35122069
  not yet assessed
• Abstract 2400: Strong biological bias for ALK intron 19 breakpoints in NSCLC ↗

  Cancer Research · 2020
  not yet assessed
• Abstract 4715: Characterization of potential co-drivers of pathogenesis in ALK positive ALCL ↗

  Cancer Research · 2020
  not yet assessed
• Abstract 2393: APOBEC3 enzymes induce chromosomal translocations in solid cancers ↗

  Cancer Research · 2020
  not yet assessed
• Abstract PO-50: Phophatases modulate resistance to ALK inhibitors in anaplastic large-cell lymphoma ↗

  Blood Cancer Discovery · 2020
  not yet assessed
• Abstract PO-17: Microphysiologic model of ALK+ anaplastic large cell lymphoma and vascular interactions predicts drug efficacy in a 3D microfluidic chip ↗

  Blood Cancer Discovery · 2020
  not yet assessed
• Microphysiological systems for modelling microvasculature and multicellular-vascular interactions using microfluidic technology

  2020
  not yet assessed
• RHO Family GTPases in the Biology of Lymphoma ↗

  Cells · 2019 · PMID 31248017
  not yet assessed
• CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation

  Cell Reports · 2019 · PMID 31365872
  L1 No data access
• Maternal immunization against ALK as a weapon to fight neuroblastoma ↗

  Annals of Oncology · 2019
  not yet assessed
• Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma ↗

  Blood · 2019
  not yet assessed
• CRISPR/Cas9 Screens Reveal Multiple Layers of B Cell CD40 Regulation ↗

  SSRN Electronic Journal · 2019
  not yet assessed
• KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS ↗

  Cell · 2018 · PMID 29336889
  not yet assessed
• Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes ↗

  Cancers · 2018 · PMID 29495603
  not yet assessed
• Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma ↗

  Nature Medicine · 2018 · PMID 30510251
  not yet assessed
• Parp3 promotes long-range end joining in murine cells ↗

  Proceedings of the National Academy of Sciences · 2018 · PMID 30213852
  not yet assessed
• The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo ↗

  Advances in experimental medicine and biology · 2018 · PMID 29956290
  not yet assessed
• Comment on “ALK is a therapeutic target for lethal sepsis” ↗

  Science Translational Medicine · 2018 · PMID 30541790
  not yet assessed
• PO-422 Development of an ALK lymphoma-derived autophagosomal and dendritic cells vaccine ↗

  ESMO Open · 2018
  not yet assessed
• PO-130 SER235 residue drives eIF6 oncogenic activity in NPM-ALK induced T cell lymphomagenesis ↗

  ESMO Open · 2018
  not yet assessed
• Parp3 promotes long-range end-joining in murine cells ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2018
  not yet assessed
• A Braf kinase-inactive mutant induces lung adenocarcinoma ↗

  Nature · 2017 · PMID 28783725
  not yet assessed
• Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells ↗

  Nature · 2017 · PMID 28199309
  not yet assessed
• Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function ↗

  Cancer Cell · 2017 · PMID 29017056
  not yet assessed
• Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1 ↗

  Clinical Immunology · 2017 · PMID 28822832
  not yet assessed
• Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization ↗

  Oncotarget · 2017 · PMID 28423635
  not yet assessed
• Developmentally‐faithful and effective human erythropoiesis in immunodeficient and <i>Kit</i> mutant mice ↗

  American Journal of Hematology · 2017 · PMID 28568895
  not yet assessed
• Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer ↗

  Oncotarget · 2017 · PMID 29190913
  not yet assessed
• Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns ↗

  Vaccines · 2017 · PMID 28763018
  not yet assessed
• Primary Cutaneous B‐Cell Lymphoblastic Lymphoma Arising from a Long‐Standing Lesion in a Child and Review of the Literature ↗

  Pediatric Dermatology · 2017 · PMID 28547875
  not yet assessed
• P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma ↗

  Journal of Thoracic Oncology · 2017
  not yet assessed
• FBXO11 Is Recurrently Mutated in Burkitt Lymphoma and Its Inactivation Accelerates Lymphomagenesis in Eμ-Myc mice ↗

  Blood · 2017
  not yet assessed
• Abstract PR10: FBXO11 is recurrently mutated in Burkitt lymphoma and its inactivation accelerates lymphomagenesis in Eμ-myc mice ↗

  Clinical Cancer Research · 2017
  not yet assessed
• P3.02a-006 Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer ↗

  Journal of Thoracic Oncology · 2017
  not yet assessed
• Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer

  BOA (University of Milano-Bicocca) · 2017
  not yet assessed
• Advances in cancer immunology and cancer immunotherapy. ↗

  PubMed · 2016 · PMID 27011048
  not yet assessed
• Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms ↗

  Proceedings of the National Academy of Sciences · 2016 · PMID 28031487
  not yet assessed
• Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system ↗

  Nature Communications · 2016 · PMID 26956543
  not yet assessed
• Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1 ↗

  Oncotarget · 2016 · PMID 27119231
  not yet assessed
• Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma ↗

  Cancer Research · 2016 · PMID 27569217
  not yet assessed
• Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice ↗

  Blood · 2016 · PMID 26747246
  not yet assessed
• Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes ↗

  eLife · 2016 · PMID 26987019
  not yet assessed
• Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia ↗

  Oncotarget · 2016 · PMID 27906678
  not yet assessed
• Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2016
  not yet assessed
• PI3KC2α, a new spindle associated protein involved in genomic instability and tumorigenesis ↗

  European Journal of Cancer · 2016
  not yet assessed
• Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP ↗

  Blood · 2016
  not yet assessed
• Author response: Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes ↗

  2016
  not yet assessed
• The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo ↗

  Cell · 2015 · PMID 25843629
  not yet assessed
• A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment ↗

  Nanomedicine Nanotechnology Biology and Medicine · 2015 · PMID 25596074
  not yet assessed
• Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors ↗

  Cancer Immunology Research · 2015 · PMID 26419961
  not yet assessed
• Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency ↗

  Oncogene · 2015 · PMID 26657151
  not yet assessed
• The anaplastic lymphoma kinase as an oncogene in solid tumors ↗

  Frontiers in Bioscience-Scholar · 2015 · PMID 25961702
  not yet assessed
• PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression ↗

  Blood · 2015
  not yet assessed
• Abstract 131: ALK oncogene regulates epithelial-mesenchymal transition (EMT) in ALK-rearranged non-small cell lung carcinoma through repression of the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) ↗

  Cancer Research · 2015
  not yet assessed
• Abstract A37: The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA. ↗

  Clinical Cancer Research · 2015
  not yet assessed
• Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency ↗

  Cancer Research · 2015
  not yet assessed
• De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC) ↗

  Blood · 2015
  not yet assessed
• FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma ↗

  Blood · 2015
  not yet assessed
• Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology ↗

  Cell Reports · 2014 · PMID 25456124
  not yet assessed
• ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis ↗

  Cancer Research · 2014 · PMID 25193384
  not yet assessed
• Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study ↗

  Lung Cancer · 2014 · PMID 24908332
  not yet assessed
• FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells ↗

  Cell Reports · 2014 · PMID 24373969
  not yet assessed
• <i>IgH</i> class switching exploits a general property of two DNA breaks to be joined <i>in cis</i> over long chromosomal distances ↗

  Proceedings of the National Academy of Sciences · 2014 · PMID 24550291
  not yet assessed
• STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. ↗

  PubMed · 2014 · PMID 25232490
  not yet assessed
• Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts ↗

  Cancer Research · 2014 · PMID 25217522
  not yet assessed
• Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma ↗

  Blood Cancer Journal · 2014 · PMID 25303368
  not yet assessed
• The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA ↗

  Blood · 2014
  not yet assessed
• 300: Loss of PI3K-C2a promotes tumorigenesis and aneuploidy in breast cancer ↗

  European Journal of Cancer · 2014
  not yet assessed
• Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing ↗

  Nature Methods · 2013 · PMID 23503052
  not yet assessed
• Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer ↗

  Gastroenterology · 2013 · PMID 23333712
  not yet assessed
• Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex ↗

  Neoplasia · 2013 · PMID 23633923
  not yet assessed
• STAT3 activity is necessary and sufficient for the development of immune‐mediated myocarditis in mice and promotes progression to dilated cardiomyopathy ↗

  EMBO Molecular Medicine · 2013 · PMID 23460527
  not yet assessed
• Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models ↗

  Journal of Hematology & Oncology · 2013 · PMID 24010981
  not yet assessed
• Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases ↗

  Cytometry Part B Clinical Cytometry · 2013 · PMID 23325563
  not yet assessed
• The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1 ↗

  Oncogenesis · 2013 · PMID 23567620
  not yet assessed
• Translocations in Normal B Cells and Cancers ↗

  Advances in immunology · 2013 · PMID 23611285
  not yet assessed
• FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells

  DSpace@MIT (Massachusetts Institute of Technology) · 2013
  not yet assessed
• Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma

  2013
  not yet assessed
• The battle against ALK resistance: successes and setbacks ↗

  Expert Opinion on Investigational Drugs · 2012 · PMID 22920921
  not yet assessed
• CALming Down T Cell Acute Leukemia ↗

  Cancer Cell · 2012 · PMID 22516253
  not yet assessed
• 874 ALK Inhibitors and Vaccination Against Anaplastic Lymphoma Kinase (ALK) Induce Potent Anti-tumor Activity Improving Overall Survival in Non Small Cell Lung Carcinoma (NSCLC) ↗

  European Journal of Cancer · 2012
  not yet assessed
• Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells ↗

  Cell · 2011 · PMID 21962511
  not yet assessed
• FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas ↗

  Nature · 2011 · PMID 22113614
  not yet assessed
• Mechanisms that Promote and Suppress Chromosomal Translocations in Lymphocytes ↗

  Annual Review of Immunology · 2011 · PMID 21219174
  not yet assessed
• Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK ↗

  Molecular Therapy · 2011 · PMID 21487394
  not yet assessed
• Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma ↗

  Molecular Therapy · 2011 · PMID 21829174
  not yet assessed
• The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway ↗

  Blood · 2011 · PMID 21518927
  not yet assessed
• Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells ↗

  Cell · 2011
  not yet assessed
• Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2011 · PMID 21599579
  not yet assessed
• The anaplastic lymphoma kinase as an oncogene in solid tumors ↗

  Frontiers in Bioscience-Scholar · 2011 · PMID 22201935
  not yet assessed
• 1007 ORAL Efficacy of DNA Vaccination Against Anaplastic Lymphoma Kinase (ALK) in Non Small Cell Lung Carcinoma (NSCLC) ↗

  European Journal of Cancer · 2011
  not yet assessed
• 9235 POSTER BCL2 Expression Correlates With Surface Immunoglobulin Levels and Prognosis in Follicular Lymphoma Patients ↗

  European Journal of Cancer · 2011
  not yet assessed
• DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer.

  2011
  not yet assessed
• The Role of Mechanistic Factors in Promoting Chromosomal Translocations Found in Lymphoid and Other Cancers ↗

  Advances in immunology · 2010 · PMID 20728025
  not yet assessed
• MT1-MMP Is Required for Myeloid Cell Fusion via Regulation of Rac1 Signaling ↗

  Developmental Cell · 2010 · PMID 20152179
  not yet assessed
• PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma ↗

  PLoS ONE · 2010 · PMID 20957039
  not yet assessed
• Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth ↗

  Journal of Biological Chemistry · 2010 · PMID 20554525
  not yet assessed
• Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytes ↗

  Immunology Letters · 2010 · PMID 20709103
  not yet assessed
• 383 Trapping and silencing of npm-alk in the nucleus is a fundamental event for npm-alk mediated cell transformation ↗

  European Journal of Cancer Supplements · 2010
  not yet assessed
• 352 Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) mediated signaling and anaplastic large cell lymphoma growth ↗

  European Journal of Cancer Supplements · 2010
  not yet assessed
• Abstract LB-309: EML4-ALK signaling is required for the maintenance of neoplastic phenotype of non-small cell lung cancer cells: Novel strategy for lung cancer-tailored therapies ↗

  Cancer Research · 2010
  not yet assessed
• 155 EML4-ALK signaling is required for the maintenance of neoplastic phenotype of non-small cell lung cancer cells: novel strategy for lung cancer tailored therapies ↗

  European Journal of Cancer Supplements · 2010
  not yet assessed
• 353 ALK kinase controls an angiogenetic program in lymphoma, lung carcinoma and neuroblastoma ↗

  European Journal of Cancer Supplements · 2010
  not yet assessed
• Reactivation of an Epigenetic Silenced Tumor Suppressor Gene BIM in Anaplastic Large Cell Lymphoma Leads to massive Apoptosis

  BOA (University of Milano-Bicocca) · 2010
  not yet assessed
• An integrated humoral and cellular response is elicited in pancreatic cancer by α‐enolase, a novel pancreatic ductal adenocarcinoma‐associated antigen ↗

  International Journal of Cancer · 2009 · PMID 19425054
  not yet assessed
• Anaplastic large cell lymphoma: one or more entities among T‐cell lymphoma? ↗

  Hematological Oncology · 2009 · PMID 19358142
  not yet assessed
• NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells ↗

  Cancer Research · 2009 · PMID 19887607
  not yet assessed
• Leukocyte transmigration is modulated by chemokine‐mediated PI3Kγ‐dependent phosphorylation of vimentin ↗

  European Journal of Immunology · 2009 · PMID 19291697
  not yet assessed
• IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival ↗

  Journal of Immunotherapy · 2009 · PMID 19816189
  not yet assessed
• IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing ↗

  Leukemia · 2009 · PMID 19626047
  not yet assessed
• Stat3 is required for anchorage‐independent growth and metastasis but not for mammary tumor development downstream of the ErbB‐2 oncogene ↗

  Molecular Carcinogenesis · 2009 · PMID 20027636
  not yet assessed
• Anaplastic lymphoma kinase: an oncogene for tumor vaccination ↗

  Journal of Molecular Medicine · 2009 · PMID 19330473
  not yet assessed
• Constitutively active Stat3 triggers the development of autoimmune myocarditis ↗

  Cytokine · 2009
  not yet assessed
• The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination ↗

  Nature Medicine · 2008 · PMID 18469826
  not yet assessed
• The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation ↗

  Cancer Research · 2008 · PMID 18974134
  not yet assessed
• Heat shock protein expression in diabetic nephropathy ↗

  American Journal of Physiology-Renal Physiology · 2008 · PMID 18922888
  not yet assessed
• The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL ↗

  Blood · 2008 · PMID 18845790
  not yet assessed
• High Energy Shock Waves (HESW) Increase Paclitaxel Efficacy in a Syngeneic Model of Breast Cancer ↗

  Technology in Cancer Research & Treatment · 2008 · PMID 18345700
  not yet assessed
• An <i>In vivo</i> Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors ↗

  Clinical Cancer Research · 2008 · PMID 18381964
  not yet assessed
• Espressione delle Heat Shock Proteins nella nefropatia diabetica sperimentale

  2008
  not yet assessed
• The anaplastic lymphoma kinase in the pathogenesis of cancer ↗

  Nature reviews. Cancer · 2007 · PMID 18097461
  not yet assessed
• The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration ↗

  Cancer Research · 2007 · PMID 17483340
  not yet assessed
• Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas ↗

  Clinical & Experimental Immunology · 2007 · PMID 17590173
  not yet assessed
• Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma ↗

  Journal of Proteome Research · 2007 · PMID 17824682
  not yet assessed
• The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase ↗

  Journal of Cell Science · 2007 · PMID 17488780
  not yet assessed
• Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase γ ↗

  Proceedings of the National Academy of Sciences · 2007 · PMID 17720808
  not yet assessed
• In the absence of IGF-1 signaling, IFN-gamma induces T cell apoptosis (94.14) ↗

  The Journal of Immunology · 2007
  not yet assessed
• Heat shock protein expression in early diabetic nephropathy

  Diabetologia · 2007
  not yet assessed
• Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity

  2007
  not yet assessed
• Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation

  2007
  not yet assessed
• Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes ↗

  Journal of Clinical Investigation · 2006 · PMID 17111047
  not yet assessed
• In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth ↗

  Blood · 2006 · PMID 17148586
  not yet assessed
• Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy ↗

  Journal of Biological Chemistry · 2006 · PMID 17194700
  not yet assessed
• Studio di polimorfismi del DNA in villi coriali isolati mediante microdissezione laser da materiale abortivo: applicazione pratica in un caso giudiziario

  2006
  not yet assessed
• Conditional expression of activated met in differentiated skeletal muscle induces atrophy

  Italian Journal of Biochemistry · 2006
  not yet assessed
• In T lymphocytes, ablation of STAT3 expression reinstates STAT1-dependent apoptosis by both IFNg and IL-6

  2006
  not yet assessed
• Anaplastic lymphoma kinase : meccanismi molecolari e trasformazione linfoide

  2006
  not yet assessed
• Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target ↗

  Nature Medicine · 2005 · PMID 15895073
  not yet assessed
• Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas ↗

  Blood · 2005 · PMID 16189272
  not yet assessed
• New and Old Functions of STAT3: A Pivitol Target for Individualized Treatment of Cancer ↗

  Cell Cycle · 2005 · PMID 16082218
  not yet assessed
• p130Cas mediates the transforming properties of the anaplastic lymphoma kinase ↗

  Blood · 2005 · PMID 16105984
  not yet assessed
• Incestuous Paternity Detected by STR‐typing of Chorionic Villi Isolated from Archival Formalin‐fixed Paraffin‐embedded Abortion Material Using Laser Microdissection ↗

  Journal of Forensic Sciences · 2005 · PMID 16423229
  not yet assessed
• RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis ↗

  Cancer Gene Therapy · 2005 · PMID 15719029
  not yet assessed
• Follicular Origin of a Subset of CD5+ Diffuse Large B-Cell Lymphomas ↗

  American Journal of Clinical Pathology · 2005 · PMID 16040287
  not yet assessed
• Follicular Origin of a Subset of CD5+ Diffuse Large B-Cell Lymphomas ↗

  American Journal of Clinical Pathology · 2005
  not yet assessed
• Identification of genomic and proteomic signatures in lymphomas by inducible shRNA

  2005
  not yet assessed
• CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation

  2005
  not yet assessed
• The STAT3 isoforms α and β have unique and specific functions ↗

  Nature Immunology · 2004 · PMID 15021879
  not yet assessed
• Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells ↗

  Journal of Biological Chemistry · 2004 · PMID 14627715
  not yet assessed
• Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei ↗

  Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2004 · PMID 14758551
  not yet assessed
• Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas. ↗

  PubMed · 2004 · PMID 15065759
  not yet assessed
• Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells

  2004
  not yet assessed
• Expression of c-kit and activated c-kit (phospho c-kit) in thymic carcinomas and WHO type B3 thymomas

  2004
  not yet assessed
• Activated KIT hyperexpression in thymic carcinoma: a potential target for therapeutic intervention.

  2004
  not yet assessed
• Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human Anaplastic Large Cell Lymphoma cells

  2004
  not yet assessed
• NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors ↗

  Blood · 2003 · PMID 12424201
  not yet assessed
• Estrogen Receptor α Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid Infiltrates ↗

  American Journal Of Pathology · 2003 · PMID 14507640
  not yet assessed
• BRAF gene is not mutated in plasma cell leukemia and multiple myeloma ↗

  Leukemia · 2003 · PMID 12931219
  not yet assessed
• Role of CD30 in the maturation of thymocytes and in the pathogenesis of autoimmune diseases. ↗

  PubMed · 2003 · PMID 14988980
  not yet assessed
• Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death ↗

  Oncogene · 2002 · PMID 11850821
  not yet assessed
• S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase ↗

  American Journal Of Pathology · 2002 · PMID 11943729
  not yet assessed
• In Vivo Interference with Skp1 Function Leads to Genetic Instability and Neoplastic Transformation ↗

  Molecular and Cellular Biology · 2002 · PMID 12417738
  not yet assessed
• Role of the F-box protein Skp2 in lymphomagenesis ↗

  Proceedings of the National Academy of Sciences · 2001 · PMID 11226270
  not yet assessed
• Induction of Germinal Centers by MMTV EncodedSuperantigen on B Cells ↗

  Journal of Immunology Research · 2001 · PMID 11785670
  not yet assessed
• Induction of germinal centers by MMTV encoded superantigen on B cells.

  Developmental & Comparative Immunology · 2001
  not yet assessed
• Stat3 and Ras activation are required for the cellular transformation mediated by NPM-ALK.

  2001
  not yet assessed
• ALK-mediated activation of STAT3 elicits growth and anti-apoptotic signals.

  2001
  not yet assessed
• Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma ↗

  Blood · 2000 · PMID 10627471
  not yet assessed
• Substitutions at Codon 22 of Alzheimer's Aβ Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells ↗

  Journal of Biological Chemistry · 2000
  not yet assessed
• The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. ↗

  Breast Cancer Research · 2000 · PMID 11250752
  not yet assessed
• Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein ΔBRCA1(17aa) ↗

  Oncogene · 2000 · PMID 10851077
  not yet assessed
• Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia ↗

  British Journal of Haematology · 2000
  not yet assessed
• Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia ↗

  British Journal of Haematology · 2000 · PMID 11091210
  not yet assessed
• Induction of germinal center formation in mmtv-vSAg7 expressing B cells by vSAg7 responsive T cells

  The FASEB Journal · 2000
  not yet assessed
• CD30 in Normal and Neoplastic Cells ↗

  Clinical Immunology · 1999 · PMID 10080826
  not yet assessed
• CD30 Overexpression Enhances Negative Selection in the Thymus and Mediates Programmed Cell Death Via a Bcl-2-Sensitive Pathway ↗

  The Journal of Immunology · 1999 · PMID 10384116
  not yet assessed
• Detection of Immunoglobulin κ Light Chain Rearrangements by Polymerase Chain Reaction ↗

  American Journal Of Pathology · 1999 · PMID 10433929
  not yet assessed
• Role of the Perivascular Epithelium in the Histogenesis of Hassall's Corpuscles ↗

  International Journal of Surgical Pathology · 1998
  not yet assessed
• CD30 mediates thymic Programmed Cell Death (PCD) through a BCL-2 sensitive pathway

  The FASEB Journal · 1998
  not yet assessed
• Parametri biologici di malignità nei linfomi di piccole cellule CD5 positivi

  1998
  not yet assessed
• Pure Alveolar Rhabdomyosarcoma of the Corpus Uteri: Description of a Case with Increased Serum Level of CA-125 ↗

  Gynecologic Oncology · 1997 · PMID 9264583
  not yet assessed
• Detection ofBCL-6 rearrangements andp53 mutations in malt-lymphomas ↗

  American Journal of Hematology · 1997 · PMID 9395180
  not yet assessed
• p53 Overexpression and Thymoma Prognosis ↗

  1997
  not yet assessed
• Cell proliferation, bcl‐2, c‐myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL) ↗

  European Journal Of Haematology · 1997 · PMID 9310122
  not yet assessed
• p53 expression and proliferative activity predict survival in non-invasive thymomas ↗

  International Journal of Cancer · 1996 · PMID 8682584
  not yet assessed
• Prognostic value of AgNORs in tumour pathology

  Analytical Cellular Pathology · 1996
  not yet assessed
• Long-term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity ↗

  The American Journal of Surgical Pathology · 1995 · PMID 7611538
  not yet assessed
• Identification of the Same HRAS1 Mutation in a Primary Minimally Invasive Follicular Carcinoma of the Thyroid Gland and its Bone Metastasis Developed 15 Years Later ↗

  Diagnostic Molecular Pathology · 1995 · PMID 7735560
  not yet assessed
• p53 overexpression, DNA ploidy and cell proliferative activity are prognostic factors in stage I-II thymomas

  Pathology - Research and Practice · 1995
  not yet assessed
• Argyrophilic nucleolar organizer region counts predict survival in thymoma ↗

  Cancer · 1994 · PMID 7520349
  not yet assessed
• Ruolo dell'Immunoistochimica nella prognosi del carcinoma della faringe: PCNA e MIB-1

  1994
  not yet assessed
• Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial ↗

  Repository@Nottingham (University of Nottingham) ·
  not yet assessed